Cargando…
Antimicrobial activity of an antimicrobial peptide against amastigote forms of Leishmania major
Zoonotic cutaneous leishmaniasis caused by Leishmania major is a most common type of vector-borne disease in Iran. The pentavalent antimonial drugs have been used in the treatment of cutaneous leishmaniasis for a long time, but drug resistance and some of serious side effects have been reported. Thu...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Urmia University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346494/ https://www.ncbi.nlm.nih.gov/pubmed/30713610 http://dx.doi.org/10.30466/vrf.2018.33107 |
_version_ | 1783389762416017408 |
---|---|
author | Khalili, Sara Mohebali, Mehdi Ebrahimzadeh, Elaheh Shayan, Ebrahimzadeh Mohammadi-Yeganeh, Samira Moosazadeh Moghaddam, Mehrdad Elikaee, Samira Akhoundi, Behnaz Sharifi-Yazdi, Mohammad Kazem |
author_facet | Khalili, Sara Mohebali, Mehdi Ebrahimzadeh, Elaheh Shayan, Ebrahimzadeh Mohammadi-Yeganeh, Samira Moosazadeh Moghaddam, Mehrdad Elikaee, Samira Akhoundi, Behnaz Sharifi-Yazdi, Mohammad Kazem |
author_sort | Khalili, Sara |
collection | PubMed |
description | Zoonotic cutaneous leishmaniasis caused by Leishmania major is a most common type of vector-borne disease in Iran. The pentavalent antimonial drugs have been used in the treatment of cutaneous leishmaniasis for a long time, but drug resistance and some of serious side effects have been reported. Thus, discovery and development of new therapeutic candidates are needed. The CM11 peptide is one of these peptides that its anti-bacterial activity has been proven. This peptide is a short cecropin–melittin hybrid peptide obtained through a sequence combination approach. The aim of this study was to evaluate in vitro anti-leishmanial activity of CM11 peptide against amastigote forms of Leishmania major. In this study, amastigote forms of Iranian strain of L. major (MRHO/IR/75/ER) were cultured in the presence of different concentrations of meglumine antimoniate (Glucantime(®)) to find the most appropriate in vitro concentration of Glucantime(®) against L. major amastigotes. Then, the anti-leishmanial activities of various concentrations of CM11 peptide (8, 16, 32 and 64 µM) were evaluated for 24, 48 and 72 hr by DAPI staining. In addition, MTT assay was used to determine the cytotoxic effects of CM11 peptide on murine fibroblast cell line. The results showed that CM11 peptide has antimicrobial activity against Iranian isolate of L. major in the laboratory conditions. It seems that the CM11 peptide has significant potential to be used as a new anti-leishmanial agent. |
format | Online Article Text |
id | pubmed-6346494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Urmia University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63464942019-02-01 Antimicrobial activity of an antimicrobial peptide against amastigote forms of Leishmania major Khalili, Sara Mohebali, Mehdi Ebrahimzadeh, Elaheh Shayan, Ebrahimzadeh Mohammadi-Yeganeh, Samira Moosazadeh Moghaddam, Mehrdad Elikaee, Samira Akhoundi, Behnaz Sharifi-Yazdi, Mohammad Kazem Vet Res Forum Original Article Zoonotic cutaneous leishmaniasis caused by Leishmania major is a most common type of vector-borne disease in Iran. The pentavalent antimonial drugs have been used in the treatment of cutaneous leishmaniasis for a long time, but drug resistance and some of serious side effects have been reported. Thus, discovery and development of new therapeutic candidates are needed. The CM11 peptide is one of these peptides that its anti-bacterial activity has been proven. This peptide is a short cecropin–melittin hybrid peptide obtained through a sequence combination approach. The aim of this study was to evaluate in vitro anti-leishmanial activity of CM11 peptide against amastigote forms of Leishmania major. In this study, amastigote forms of Iranian strain of L. major (MRHO/IR/75/ER) were cultured in the presence of different concentrations of meglumine antimoniate (Glucantime(®)) to find the most appropriate in vitro concentration of Glucantime(®) against L. major amastigotes. Then, the anti-leishmanial activities of various concentrations of CM11 peptide (8, 16, 32 and 64 µM) were evaluated for 24, 48 and 72 hr by DAPI staining. In addition, MTT assay was used to determine the cytotoxic effects of CM11 peptide on murine fibroblast cell line. The results showed that CM11 peptide has antimicrobial activity against Iranian isolate of L. major in the laboratory conditions. It seems that the CM11 peptide has significant potential to be used as a new anti-leishmanial agent. Urmia University Press 2018 2018-12-15 /pmc/articles/PMC6346494/ /pubmed/30713610 http://dx.doi.org/10.30466/vrf.2018.33107 Text en © 2018 Urmia University. This is an open-access article distributed under the terms of the Creative Commons Attribution-noncommercial 4.0 International License, (https://creativecommons.org/licenses/by-nc/4.0/) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly. |
spellingShingle | Original Article Khalili, Sara Mohebali, Mehdi Ebrahimzadeh, Elaheh Shayan, Ebrahimzadeh Mohammadi-Yeganeh, Samira Moosazadeh Moghaddam, Mehrdad Elikaee, Samira Akhoundi, Behnaz Sharifi-Yazdi, Mohammad Kazem Antimicrobial activity of an antimicrobial peptide against amastigote forms of Leishmania major |
title | Antimicrobial activity of an antimicrobial peptide against amastigote forms of Leishmania major
|
title_full | Antimicrobial activity of an antimicrobial peptide against amastigote forms of Leishmania major
|
title_fullStr | Antimicrobial activity of an antimicrobial peptide against amastigote forms of Leishmania major
|
title_full_unstemmed | Antimicrobial activity of an antimicrobial peptide against amastigote forms of Leishmania major
|
title_short | Antimicrobial activity of an antimicrobial peptide against amastigote forms of Leishmania major
|
title_sort | antimicrobial activity of an antimicrobial peptide against amastigote forms of leishmania major |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346494/ https://www.ncbi.nlm.nih.gov/pubmed/30713610 http://dx.doi.org/10.30466/vrf.2018.33107 |
work_keys_str_mv | AT khalilisara antimicrobialactivityofanantimicrobialpeptideagainstamastigoteformsofleishmaniamajor AT mohebalimehdi antimicrobialactivityofanantimicrobialpeptideagainstamastigoteformsofleishmaniamajor AT ebrahimzadehelaheh antimicrobialactivityofanantimicrobialpeptideagainstamastigoteformsofleishmaniamajor AT shayanebrahimzadeh antimicrobialactivityofanantimicrobialpeptideagainstamastigoteformsofleishmaniamajor AT mohammadiyeganehsamira antimicrobialactivityofanantimicrobialpeptideagainstamastigoteformsofleishmaniamajor AT moosazadehmoghaddammehrdad antimicrobialactivityofanantimicrobialpeptideagainstamastigoteformsofleishmaniamajor AT elikaeesamira antimicrobialactivityofanantimicrobialpeptideagainstamastigoteformsofleishmaniamajor AT akhoundibehnaz antimicrobialactivityofanantimicrobialpeptideagainstamastigoteformsofleishmaniamajor AT sharifiyazdimohammadkazem antimicrobialactivityofanantimicrobialpeptideagainstamastigoteformsofleishmaniamajor |